



## IHC image of neurons in rat supraoptic nucleus.

## C-FOS Antibody

Catalog #	26209	Product type	Primary antibodies
Lot #	1714001	Clonality	Polyclonal
Form	Lyophilized whole serum (100 µL)	Isotype	IgG
Host	Rabbit	Preservative	≤ 0.09% sodium azide
Reacts With	Mouse, Rat	Antigen	Synthetic peptide sequence corresponding to (human) C-FOS (4–17) coupled to Hc with glutaraldehyde
INSTRUCTIONS			
Preparation	Do not reconstitute until ready to use since the product is most stable when lyophilized. The product does not need to be kept cooled during shipping; however, for long-term storage, store lyophilized antibod, until ready to use at -15°C or lower. Reconstitute with 100 $\mu$ L of distilled or deionized water. After reconstitution, use immediately or refrigerate at 2°-8°C. To avoid freeze/thaw cycles, dilute unused antibody with PBS or Tris buffer at a dilution no higher than 1/10, then aliquot and freeze at -15°C or lower.		
	Refer to the Instruction Manual available online at www.immunostar.com for information on tissue preparation, immunostaining techniques, troubleshooting, and formulas.		
APPLICATION			
IHC Quality Control	For induction of c-Fos protein activity, rats were injected with 1.0 ml of 1.5 M NaCl per 100 grams of body weight. Negative control rats were injected with the same volume of normal saline. The ImmunoStar c-Fo antiserum was quality control tested using standard immunohistochemical methods. The antiserum demonstrates significant labeling of rat paraventricular and supraoptic nuclei using indirect immunofluorescent and biotin/avidin-HRP techniques. The antibody was also validated by challenge with the selective 5HT2a agonist TCB2 (10 mg/kg ip) with results showing massive numbers of cortical pyramidal cells of the TCB2 treated rats, consistent with the distribution of 5HT2a receptors. No labeling was seen in negative control rats. Specificity of the antiserum was demonstrated by blockage of staining ir experimental rats by omission of c-Fos antibody or by substitution of antibody pre-incubated with synthetic peptide or the conjugate.		
	the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated ra was seen in negative control rats. Spe experimental rats by omission of c-Fos	IRP techniques. The mg/kg ip) with resul ts, consistent with the ecificity of the antise	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining
Tissue	the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated ra was seen in negative control rats. Spe experimental rats by omission of c-Fos	IRP techniques. The mg/kg ip) with resul ts, consistent with th ecificity of the antise s antibody or by sub	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining i stitution of antibody pre-incubated with synthetic
Tissue Perfusion Fixation	<ul> <li>the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated ra was seen in negative control rats. Spe experimental rats by omission of c-Fos peptide or the conjugate.</li> <li>Rat brain hypothalamus (paraventricul</li> <li>Fixative: 4% paraformaldehyde-0.05 30 min.</li> </ul>	IRP techniques. The mg/kg ip) with resul ts, consistent with th ecificity of the antise s antibody or by sub- ar and supraoptic no % glutaraldehye in 0	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining stitution of antibody pre-incubated with synthetic
	<ul> <li>the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated ra was seen in negative control rats. Spe experimental rats by omission of c-Fos peptide or the conjugate.</li> <li>Rat brain hypothalamus (paraventricul</li> <li>Fixative: 4% paraformaldehyde-0.05 30 min.</li> <li>Post Fixation: 1.5 hour at 4°C in 4%</li> </ul>	IRP techniques. The mg/kg ip) with resul ts, consistent with th ecificity of the antise s antibody or by sub- ar and supraoptic no % glutaraldehye in 0	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining stitution of antibody pre-incubated with synthetic uclei) and cortex. 0.1M Phosphate buffer, pH 7.4; 500 mL over 20-
Perfusion Fixation	<ul> <li>the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated rawas seen in negative control rats. Speexperimental rats by omission of c-Fospeptide or the conjugate.</li> <li>Rat brain hypothalamus (paraventricule)</li> <li>Fixative: 4% paraformaldehyde-0.05 30 min.</li> <li>Post Fixation: 1.5 hour at 4°C in 4% pH 7.4.</li> </ul>	IRP techniques. The mg/kg ip) with resul ts, consistent with th ecificity of the antise s antibody or by sub- ar and supraoptic no % glutaraldehye in 0	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining stitution of antibody pre-incubated with synthetic uclei) and cortex. 0.1M Phosphate buffer, pH 7.4; 500 mL over 20
Perfusion Fixation Sections	<ul> <li>the selective 5HT2a agonist TCB2 (10 pyramidal cells of the TCB2 treated ra was seen in negative control rats. Speexperimental rats by omission of c-Fos peptide or the conjugate.</li> <li>Rat brain hypothalamus (paraventricul</li> <li>Fixative: 4% paraformaldehyde-0.05 30 min.</li> <li>Post Fixation: 1.5 hour at 4°C in 4% pH 7.4.</li> <li>50 µm vibratome</li> </ul>	IRP techniques. The mg/kg ip) with resul ts, consistent with th ecificity of the antise s antibody or by sub- ar and supraoptic no % glutaraldehye in 0 paraformaldehyde-0	e antibody was also validated by challenge with ts showing massive numbers of cortical e distribution of 5HT2a receptors. No labeling rum was demonstrated by blockage of staining stitution of antibody pre-incubated with synthetic uclei) and cortex. 0.1M Phosphate buffer, pH 7.4; 500 mL over 20 0.05% glutaraldehye in 0.1M phosphate buffer,

Special Instructions	It is recommended that the researcher perform a primary antibody dilution series using our dilution recommendations as a guideline. Note that a change in the fixation or buffering system from our protocol may change the configuration of the protein which could alter the reactivity with the tissue tested.
Long-Term Storage	After reconstitution, use immediately or refrigerate at 2°–8°C up to 2 days. For long-term storage, aliquot and freeze at -15°C or lower. Avoid repeated freeze/thaw cycles.
Concentration	Not applicable. Antibody concentration is only relevant for purified antibodies.
Journal References	www.immunostar.com/publications

For Laboratory Reagent Use Only. Analytical and performance characteristics are not established.

ALL PRODUCTS ARE FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE RRID:AB\_572267